MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)‐dependent oncogenic driver in vitro and in humanised HGF knock‐in mice

Exon skipping mutations of the MET receptor tyrosine kinase (METex14), increasingly reported in cancers, occur in 3–4% of non–small‐cell lung cancer (NSCLC). Only 50% of patients have a beneficial response to treatment with MET‐tyrosine kinase inhibitors (TKIs), underlying the need to understand the...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandes, Marie, Hoggard, Brynna, Jamme, Philippe, Paget, Sonia, Truong, Marie‐José, Grégoire, Valérie, Vinchent, Audrey, Descarpentries, Clotilde, Morabito, Angela, Stanislovas, Justas, Farage, Enoir, Meneboo, Jean‐Pascal, Sebda, Shéhérazade, Bouchekioua‐Bouzaghou, Katia, Nollet, Marie, Humez, Sarah, Perera, Timothy, Fromme, Paul, Grumolato, Luca, Figeac, Martin, Copin, Marie‐Christine, Tulasne, David, Cortot, Alexis B., Kermorgant, Stéphanie, Kherrouche, Zoulika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620121/
https://www.ncbi.nlm.nih.gov/pubmed/36799689
http://dx.doi.org/10.1002/1878-0261.13397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620121/
https://www.ncbi.nlm.nih.gov/pubmed/36799689
http://dx.doi.org/10.1002/1878-0261.13397

Ejemplares similares